| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | cabozantinib (Cabometyx®) |
| Formulation | 20 mg, 40 mg, 60 mg film-coated tablet |
| Reference number | 2257 |
| Indication | Treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy |
| Company | Ipsen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/09/2016 |
| NICE guidance | TA463: Cabozantinib for previously treated advanced renal cell carcinoma |